Journal article

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms

BS Wyspianska, AJ Bannister, I Barbieri, J Nangalia, A Godfrey, FJ Calero-Nieto, S Robson, I Rioja, J Li, M Wiese, E Cannizzaro, MA Dawson, B Huntly, RK Prinjha, AR Green, B Gottgens, T Kouzarides

Leukemia | NATURE PUBLISHING GROUP | Published : 2014

Grants

Awarded by Biotechnology and Biological Sciences Research Council


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Awarded by National Centre for the Replacement


Funding Acknowledgements

We thank members of the Kouzarides laboratory for the thoughtful discussion. The Kouzarides laboratory was supported by Cancer Research UK, Leukaemia and Lymphoma Research, GlaxoSmithKline and BBSRC. Work in the Green laboratory is supported by Leukemia and Lymphoma Research, Cancer Research UK, the Kay Kendall Leukaemia Fund, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and the Leukemia and Lymphoma Society of America. The Gottgens laboratory was supported by Cancer Research UK and Leukaemia and Lymphoma Research, UK. The Huntly laboratory was supported by Cancer Research UK and Leukaemia and Lymphoma Research, UK. MA Dawson is a Wellcome Trust Beit Fellow and E Cannizzaro and M Wiese are funded by this Fellowship.